These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8996122)

  • 1. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.
    Saven A; Lee T; Schlutz M; Jacobs A; Ellison D; Longmire R; Piro L
    J Clin Oncol; 1997 Jan; 15(1):37-43. PubMed ID: 8996122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of prolymphocytic leukemia with cladribine.
    Lorand-Metze I; Oliveira GB; Aranha FJ
    Ann Hematol; 1998 Feb; 76(2):85-6. PubMed ID: 9540763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
    Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
    J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.
    Shvidel L; Shtalrid M; Bassous L; Klepfish A; Vorst E; Berrebi A
    Leuk Lymphoma; 1999 Mar; 33(1-2):169-79. PubMed ID: 10194135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
    Montillo M; Tedeschi A; O'Brien S; Di Raimondo F; Lerner S; Ferrajoli A; Morra E; Keating MJ
    Cancer; 2003 Jan; 97(1):114-20. PubMed ID: 12491512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
    Saven A; Piro LD; Lemon RH; Figueroa ML; Kosty M; Ellison DJ; Beutler E
    Cancer; 1994 Jun; 73(12):2953-63. PubMed ID: 7911068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.
    Jäger G; Neumeister P; Brezinschek R; Hinterleitner T; Fiebiger W; Penz M; Neumann HJ; Mlineritsch B; DeSantis M; Quehenberger F; Chott A; Beham-Schmid C; Höfler G; Linkesch W; Raderer M
    J Clin Oncol; 2002 Sep; 20(18):3872-7. PubMed ID: 12228207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
    Rondelli D; Lauria F; Zinzani PL; Raspadori D; Ventura MA; Galieni P; Birtolo S; Forconi F; Algeri R; Tura S
    Eur J Haematol; 1997 Jan; 58(1):46-50. PubMed ID: 9020373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment options in prolymphocytic leukemia.
    Robak T; Robak P
    Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia.
    Rai KR
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):19-22. PubMed ID: 9671325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
    Tallman MS; Hakimian D; Zanzig C; Hogan DK; Rademaker A; Rose E; Variakojis D
    J Clin Oncol; 1995 Apr; 13(4):983-8. PubMed ID: 7707127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
    Blum KA; Johnson JL; Niedzwiecki D; Piro LD; Saven A; Peterson BA; Byrd JC; Cheson BD;
    Cancer; 2006 Dec; 107(12):2817-25. PubMed ID: 17120198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
    Hoffman MA; Janson D; Rose E; Rai KR
    J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
    Krykowski E; Warzocha K; Robak T
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.